NUT正中線がん治療の市場規模、シェア、動向分析レポート：治療別、投与経路別、最終用途別、地域別、セグメント別予測、2024年～2030年

NUT正中線がん治療市場の成長と動向：

Grand View Research, Inc.の調査レポートによると、世界のNUT正中線がん治療の市場規模は2030年までに441億米ドルに達し、CAGR 12.4％で成長すると予測されています。

この著しい成長は、希少がん種に対する認識の高まり、標的療法の進歩、精密医療への注目の高まりが主な要因です。診断ツールの進歩とヘルスケア専門家の意識の向上により、より多くの症例が早期に発見されるようになり、効果的な治療に対する需要の高まりにつながっています。

標的治療薬、特にエピジェネティックなメカニズムに注目した治療薬の台頭は、この市場において極めて重要です。例えば、NMCとよく関連するBRD4-NUT融合タンパク質を標的とするBET（ブロモドメインおよびエクストラターミナル）阻害剤の開発は、治療の新たな道を開きました。ブリストル・マイヤーズスクイブ社などはこの研究の最前線にあり、現在臨床試験中のトロタブレシブ（CC-90010）などの薬剤を開発しています。この疾患の侵攻性と予後の悪さから、新しい治療法の開発が強く求められています。この疾患は希少であるため、臨床試験用の患者数が限られており、包括的な疫学データが不足しているなどの課題もあります。

政府や規制機関も、NMC治療開発を加速させる上で重要な役割を果たしています。米国や欧州を含む多くの地域で、NMCは希少疾病に指定されており、この希少がんの治療法を開発する企業に税額控除や市場独占権の延長などのインセンティブを提供しています。これらの優遇措置は、患者数が少ないために制限されているNMC研究への投資を促進する上で極めて重要です。

NUT正中線がん治療市場レポートハイライト

• 2023年、化学療法セグメントはNUT正中線がん治療市場において32.5%の最大収益シェアを占めました。
• 静脈内セグメントは、2023年に68.7%の最大の収益シェアを占めます。これは、バイオアベイラビリティーが高く、血流への薬物のより迅速な送達により、強力な治療法が確実に腫瘍細胞に到達するため、NMC管理における速効性治療の必要性が原動力となっています。経口薬よりも効果的です。
• 専門クリニックは予測期間中に13.5％のCAGRを達成すると予測されています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 NUT正中線がん治療市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場成長要因分析
  • 市場抑制要因分析
• NUT正中線がん治療市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析

第4章 NUT正中線がん治療市場：治療別の推定・動向分析

• 世界のNUT正中線がん治療市場：治療別 - ダッシュボード
• 世界のNUT正中線がん治療市場：治療別 - 変動分析
• 世界のNUT正中線がん治療市場：治療別 - 収益
• 化学療法
• 標的療法
• 免疫療法
• 放射線治療
• その他

第5章 NUT正中線がん治療市場： 投与経路別の推定・動向分析

• 世界のNUT正中線がん治療市場：投与経路別 - ダッシュボード
• 世界のNUT正中線がん治療市場：投与経路別 - 変動分析
• 世界のNUT正中線がん治療市場：投与経路別 - 収益
• 経口
• 静脈内
• その他

第6章 NUT正中線がん治療市場：最終用途別の推定・動向分析

• 世界のNUT正中線がん治療市場：最終用途別 - ダッシュボード
• 世界のNUT正中線がん治療市場：最終用途別 - 変動分析
• 世界のNUT正中線がん治療市場：最終用途別 - 収益
• 病院
• 専門クリニック
• その他

第7章 NUT正中線がん治療市場：地域別の推定・動向分析

• 地域別 - ダッシュボード
• 市場規模と予測動向分析、2018年～2030年：
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第8章 競合情勢

• 企業/競合の分類
• ベンダー情勢
  • 主要販売代理店およびチャネルパートナーのリスト
  • 主要企業の市場シェア分析、2023年
  • Merck &Co. Inc
  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd
  • C4 Therapeutics, Inc.
  • Ipsen Biopharmaceuticals, Inc
  • GSK plc

List of Tables

• Table 1 List Of Abbreviation
• Table 2 North America NUT Midline Carcinoma Treatment Market, By Region, 2018 - 2030 (USD Million)
• Table 3 North America NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 4 North America NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 5 North America NUT Midline Carcinoma Treatment Market, End Use, 2018 - 2030 (USD Million)
• Table 6 U.S. NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 7 U.S. NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 8 U.S. NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 9 Canada NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 10 Canada NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 11 Canada NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 12 Mexico NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 13 Mexico NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 14 Mexico NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 15 Europe NUT Midline Carcinoma Treatment Market, By Region, 2018 - 2030 (USD Million)
• Table 16 Europe NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 17 Europe NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 18 Europe NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 19 Germany NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 20 Germany NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 21 Germany NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 22 UK NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 23 UK NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 24 UK NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 25 France NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 26 France NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 27 France NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 28 Italy NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 29 Italy NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 30 Italy NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 31 Spain NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 32 Spain NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 33 Spain NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 34 Denmark NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 35 Denmark NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 36 Denmark NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 37 Sweden NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 38 Sweden NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 39 Sweden NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 40 Norway NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 41 Norway NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 42 Norway NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 43 Asia Pacific NUT Midline Carcinoma Treatment Market, By Region, 2018 - 2030 (USD Million)
• Table 44 Asia Pacific NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 45 Asia Pacific NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 46 Asia Pacific NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 47 China NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 48 China NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 49 China NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 50 Japan NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 51 Japan NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 52 Japan NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 53 India NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 54 India NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 55 India NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 56 South Korea NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 57 South Korea NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 58 South Korea NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 59 Australia NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 60 Australia NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 61 Australia NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 62 Thailand NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 63 Thailand NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 64 Thailand NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 65 Latin America NUT Midline Carcinoma Treatment Market, By Region, 2018 - 2030 (USD Million)
• Table 66 Latin America NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 67 Latin America NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 68 Latin America NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 69 Brazil NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 70 Brazil NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 71 Brazil NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 72 Argentina NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 73 Argentina NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 74 Argentina NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 75 MEA NUT Midline Carcinoma Treatment Market, By Region, 2018 - 2030 (USD Million)
• Table 76 MEA NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 77 MEA NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 78 MEA NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 79 South Africa NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 80 South Africa NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 81 South Africa NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 82 Saudi Arabia NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 83 Saudi Arabia NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 84 Saudi Arabia NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 85 UAE NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 86 UAE NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 87 UAE NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
• Table 88 Kuwait NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
• Table 89 Kuwait NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 90 Kuwait NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews in North America
• Fig. 5 Primary interviews in Europe
• Fig. 6 Primary interviews in APAC
• Fig. 7 Primary interviews in Latin America
• Fig. 8 Primary interviews in MEA
• Fig. 9 Market research approaches
• Fig. 10 Value-chain-based sizing & forecasting
• Fig. 11 QFD modeling for market share assessment
• Fig. 12 Market formulation & validation
• Fig. 13 NUT midline carcinoma Treatment Market: Market Outlook
• Fig. 14 NUT midline carcinoma Treatment Competitive Insights
• Fig. 15 Parent market outlook
• Fig. 16 Related/ancillary market outlook
• Fig. 17 NUT midline carcinoma Treatment Market Driver Impact
• Fig. 18 NUT midline carcinoma Treatment Market Restraint Impact
• Fig. 19 NUT midline carcinoma Treatment Market Strategic Initiatives Analysis
• Fig. 20 NUT midline carcinoma Treatment Market: Treatment Movement Analysis
• Fig. 21 NUT midline carcinoma Treatment Market: Treatment Outlook and Key Takeaways
• Fig. 22 Chemotherapy market estimates and forecast, 2018 - 2030
• Fig. 23 Targeted therapy market estimates and forecast, 2018 - 2030
• Fig. 24 Immunotherapy market estimates and forecast, 2018 - 2030
• Fig. 25 Radiation therapy market estimates and forecast, 2018 - 2030
• Fig. 26 Other market estimates and forecast, 2018 - 2030
• Fig. 27 NUT midline carcinoma Treatment Market: Route of Administration Movement Analysis
• Fig. 28 NUT midline carcinoma Treatment Market: Route of Administration Outlook and Key Takeaways
• Fig. 29 Oral market estimates and forecast, 2018 - 2030
• Fig. 30 Intravenous market estimates and forecast, 2018 - 2030
• Fig. 31 Other market estimates and forecast, 2018 - 2030
• Fig. 32 NUT midline carcinoma Treatment Market: End Use Movement Analysis
• Fig. 33 NUT midline carcinoma Treatment Market: End Use Outlook and Key Takeaways
• Fig. 34 Hospitals market estimates and forecast, 2018 - 2030
• Fig. 35 Specialty clinics market estimates and forecast, 2018 - 2030
• Fig. 36 Other market estimates and forecast, 2018 - 2030
• Fig. 37 Global NUT midline carcinoma Treatment Market: Regional Movement Analysis
• Fig. 38 Global NUT midline carcinoma Treatment Market: Regional Outlook and Key Takeaways
• Fig. 39 Global NUT midline carcinoma Treatment market share and leading players
• Fig. 40 North America, by country
• Fig. 41 North America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 42 U.S. key country dynamics
• Fig. 43 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 44 Canada key country dynamics
• Fig. 45 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 46 Mexico key country dynamics
• Fig. 47 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 48 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 49 UK key country dynamics
• Fig. 50 UK market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 51 Germany key country dynamics
• Fig. 52 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 53 France key country dynamics
• Fig. 54 France market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 55 Italy key country dynamics
• Fig. 56 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 57 Spain key country dynamics
• Fig. 58 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 59 Denmark key country dynamics
• Fig. 60 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 61 Sweden key country dynamics
• Fig. 62 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 63 Norway key country dynamics
• Fig. 64 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 65 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 66 China key country dynamics
• Fig. 67 China market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 68 Japan key country dynamics
• Fig. 69 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 70 India key country dynamics
• Fig. 71 India market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 72 Thailand key country dynamics
• Fig. 73 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 74 South Korea key country dynamics
• Fig. 75 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 76 Australia key country dynamics
• Fig. 77 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 78 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 79 Brazil key country dynamics
• Fig. 80 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 81 Argentina key country dynamics
• Fig. 82 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 83 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 84 South Africa key country dynamics
• Fig. 85 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 86 Saudi Arabia key country dynamics
• Fig. 87 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 88 UAE key country dynamics
• Fig. 89 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 90 Kuwait key country dynamics
• Fig. 91 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 92 Market share of key market players- NUT midline carcinoma Treatment market

NUT Midline Carcinoma Treatment Market Growth & Trends:

The global NUT midline carcinoma treatment market size is anticipated to reach USD 44.1 billion by 2030, growing at a CAGR of 12.4%, according to a report by Grand View Research, Inc. This significant growth is majorly driven by the increasing awareness of rare cancer types, advancements in targeted therapies, and the growing focus on precision medicine. With advancements in diagnostic tools and greater awareness among healthcare professionals, more cases are being identified earlier, leading to an increased demand for effective treatments.

The rise of targeted therapies, particularly those focusing on epigenetic mechanisms, has been pivotal in this market. For instance, the development of BET (bromodomain and extra-terminal) inhibitors, which target the BRD4-NUT fusion protein commonly associated with NMC, has opened new avenues for treatment. Companies such as Bristol-Myers Squibb are at the forefront of this research, developing drugs such as Trotabresib (CC-90010), which are currently in clinical trials. The aggressive nature of the disease and the poor prognosis associated with it create a strong imperative for the development of new therapies. The rarity of the disease also presents challenges, including limited patient pools for clinical trials and a lack of comprehensive epidemiological data.

Government and regulatory bodies are also playing a crucial role in accelerating the development of NMC treatments. In many regions, including the U.S. and Europe, NMC has been granted orphan disease status, providing incentives such as tax credits and extended market exclusivity to companies developing treatments for this rare cancer. These incentives are critical in encouraging investment in NMC research, which is otherwise limited due to the small patient population.

NUT Midline Carcinoma Treatment Market Report Highlights:

• In 2023, the chemotherapy segment accounted for the largest revenue share of 32.5% in NUT midline carcinoma treatment market.
• The intravenous segment accounts for the largest revenue share of 68.7% in 2023 driven by the need for fast-acting treatments in managing NMC due to its higher bioavailability and quicker delivery of the drug to the bloodstream, ensuring that the potent therapies reach the tumor cells more effectively than oral medications might.
• Specialty clinics are anticipated to achieve the highest CAGR of 13.5% during the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Treatment
  • 1.2.2. Route of Administration
  • 1.2.3. End Use
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Treatment Outlook
  • 2.2.2. Route of Administration
  • 2.2.3. End Use
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. NUT midline carcinoma Treatment Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising Prevalence NUT Midline Carcinoma
    • 3.2.1.2. Advancement in Diagnostics
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High Diagnostic Challenges
    • 3.2.2.2. Limited Awareness
• 3.3. NUT midline carcinoma Treatment Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. NUT midline carcinoma Treatment Market: Treatment Estimates & Trend Analysis

• 4.1. Global NUT midline carcinoma Treatment Market: Treatment Dashboard
• 4.2. Global NUT midline carcinoma Treatment Market: Treatment Movement Analysis
• 4.3. Global NUT midline carcinoma Treatment Market by Treatment, Revenue
• 4.4. Chemotherapy
  • 4.4.1. Chemotherapy market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Targeted Therapy
  • 4.5.1. Targeted Therapy market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Immunotherapy
  • 4.6.1. Immunotherapy market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Radiation Therapy
  • 4.7.1. Radiation Therapy market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Others
  • 4.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. NUT midline carcinoma Treatment Market: Route of Administration Estimates & Trend Analysis

• 5.1. Global NUT midline carcinoma Treatment Market: Route of Administration Dashboard
• 5.2. Global NUT midline carcinoma Treatment Market: Route of Administration Movement Analysis
• 5.3. Global NUT midline carcinoma Treatment Market Estimates and Forecasts, By Route of Administration, Revenue (USD Million)
• 5.4. Oral
  • 5.4.1. Oral market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Intravenous
  • 5.5.1. Intravenous market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Other
  • 5.6.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. NUT midline carcinoma Treatment Market: End Use Estimates & Trend Analysis

• 6.1. Global NUT midline carcinoma Treatment Market: End Use Dashboard
• 6.2. Global NUT midline carcinoma Treatment Market: End Use Movement Analysis
• 6.3. Global NUT midline carcinoma Treatment Market Estimates and Forecasts, By End Use, Revenue (USD Million)
• 6.4. Hospitals
  • 6.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Specialty Clinics
  • 6.5.1. Specialty clinics market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Other
  • 6.6.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. NUT midline carcinoma Treatment Market: Regional Estimates & Trend Analysis

• 7.1. Regional Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.3. Mexico
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework/ reimbursement structure
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company/Competition Categorization
• 8.2. Vendor Landscape
  • 8.2.1. List of key distributors and channel partners
  • 8.2.2. Key company market share analysis, 2023
  • 8.2.3. Merck & Co. Inc
    • 8.2.3.1. Company overview
    • 8.2.3.2. Financial performance
    • 8.2.3.3. Product benchmarking
    • 8.2.3.4. Strategic initiatives
  • 8.2.4. Bristol-Myers Squibb Company
    • 8.2.4.1. Company overview
    • 8.2.4.2. Financial performance
    • 8.2.4.3. Product benchmarking
    • 8.2.4.4. Strategic initiatives
  • 8.2.5. Pfizer Inc.
    • 8.2.5.1. Company overview
    • 8.2.5.2. Financial performance
    • 8.2.5.3. Product benchmarking
    • 8.2.5.4. Strategic initiatives
  • 8.2.6. F. Hoffmann-La Roche Ltd
    • 8.2.6.1. Company overview
    • 8.2.6.2. Financial performance
    • 8.2.6.3. Product benchmarking
    • 8.2.6.4. Strategic initiatives
  • 8.2.7. C4 Therapeutics, Inc.
    • 8.2.7.1. Company overview
    • 8.2.7.2. Financial performance
    • 8.2.7.3. Product benchmarking
    • 8.2.7.4. Strategic initiatives
  • 8.2.8. Ipsen Biopharmaceuticals, Inc
    • 8.2.8.1. Company overview
    • 8.2.8.2. Financial performance
    • 8.2.8.3. Product benchmarking
    • 8.2.8.4. Strategic initiatives
  • 8.2.9. GSK plc
    • 8.2.9.1. Company overview
    • 8.2.9.2. Financial performance
    • 8.2.9.3. Product benchmarking
    • 8.2.9.4. Strategic initiatives